Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends

Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.

Raccontata dabiopharmadive.com